Imfinzi Drug Interactions

Durvalumab is an immunoglobulin, therefore no formal pharmacokinetic drug-drug interaction studies have been conducted with durvalumab. PK drug-drug interaction of durvalumab with other medicinal products are not anticipated given durvalumab is not primarily cleared via hepatic/renal pathways but instead the primary elimination pathways are protein catabolism via reticuloendothelial system or target-mediated disposition. Durvalumab is not expected to induce or inhibit the major drug metabolizing cytochrome P450 pathways.
The pharmacokinetics of durvalumab is similar when assessed as a single agent and when in combination with chemotherapy.
The use of systemic corticosteroids or immunosuppressants before starting durvalumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of durvalumab. However, systemic corticosteroids or other immunosuppressants can be used after starting durvalumab to treat immune-related adverse reactions (see Precautions).
PK drug-drug interaction between durvalumab and chemotherapy was assessed in the CASPIAN study and no clinically meaningful PK drug-drug interaction was identified. PK drug-drug interaction between durvalumab in combination with tremelimumab and platinum-based chemotherapy was assessed in the POSEIDON study and no clinically meaningful PK drug-drug interaction was identified. PK drug-drug interaction between durvalumab in combination with tremelimumab was assessed in the HIMALAYA study and no clinically meaningful PK drug-drug interaction was identified.